Across TCGA pan-cancer cohorts, C16orf54 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated C16orf54 data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher C16orf54 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated C16orf54 expression acts as an unfavorable survival marker.

LIHC, COAD, and UCEC are the cancer types where C16orf54 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.038	0.556	<.001	12	view →
COAD	DFS	Median	IV	0.035	0.501	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SCLC	DFS	Median	All	0.214	0.503	.028	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: C16orf54 tumor-vs-normal RNA expression · all C16orf54 data types